Basic Information
| Drug ID | DDPD00863 |
|
| Drug Name | Ranitidine | |
| Molecular Weight | 314.4 | |
| Molecular Formula | C13H22N4O3S | |
| CAS Number | 66357-35-5 | |
| SMILES | CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O | |
| External Links | ||
| DRUGBANK | DB00863 | |
| PubChem Compound | 3001055 | |
| PDR | 239 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Caco-2 Permeability | 0.49 | - | 0.49 | - | https://www.ncbi.nlm.nih.gov/pubmed/9755906 |
| Log P | 0.2 | - | 0.2 | - | https://www.fip.org/files/fip/BPS/BCS/Monographs/Ranitidine_Hydrochloride.pdf |
| Boiling Point | 437.1 | ℃ | 437.1±45.0 | ℃ | http://www.chemspider.com/Chemical-Structure.571454.html |
| Melting Point | 134.0 | ℃ | 134 | ℃ | https://www.chemicalbook.com/ChemicalProductProperty_US_CB3685534.aspx |
| pKa | 8.2 | - | 8.2,2.7 | - | https://www.fip.org/files/fip/BPS/BCS/Monographs/Ranitidine_Hydrochloride.pdf | pKa | 2.7 | - | 8.2,2.7 | - | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| AUC | 2488.6 | ng.h/ml | 2488.6 | ng.h/ml | PO, oral; Male, men; normal,healthy; | DRUGBANK | |
| Bioavailability | 55.0 | % | 50-60 | % | PO, oral; | DRUGBANK | Bioavailability | 52.0 | % | 52±11 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 462.0 | ng/ml | 462±54 | ng/ml | Oral single dose; adults; normal,healthy; | The Pharmacological Basis of Therapeutics | |
| T Max | 2.0 | h | 1-3 | h | PO, oral; | DRUGBANK | T Max | 2.8 | h | 2.83 | h | PO, oral; Male, men; normal,healthy; | DRUGBANK | T Max | 2.1 | h | 2.1±0.31 | h | Oral single dose; adults; normal,healthy; | The Pharmacological Basis of Therapeutics |
| Metabolic | 4.0 | % | 4 | % | Urinary excretion; | DRUGBANK | Metabolic | 1.0 | % | 1 | % | Urinary excretion; | DRUGBANK | Metabolic | 1.0 | % | 1 | % | Urinary excretion; | DRUGBANK |
| Clearance | 24.6 | L/h | 410.0 | ml/min | Renal clearance; | DRUGBANK | Clearance | 36.0 | L/h | ~600 | ml/min | Plasma clearance; | DRUGBANK | Clearance | 0.62 | L/h/kg | 10.4±1.1 | ml/min/kg | Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.58 | L/h/kg | 9.6 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.4 | L/kg | ~1.4 | L/kg | DRUGBANK | Volume of Distribution | 1.3 | L/kg | 1.3±0.4 | L/kg | Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia → ;Burn ↑ ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.2 | L/kg | 1.2 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 2.8 | h | ~2.5-3 | h | elimination half-life; | DRUGBANK | Half-life | 3.5 | h | 3-4 | h | elimination half-life; patients; | DRUGBANK | Half-life | 2.1 | h | 2.1±0.2 | h | RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;Burn → ;Age ↑ ; | The Pharmacological Basis of Therapeutics | Half-life | 2.1 | h | 2.1 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 77.0 | mg/kg | 77.0 | mg/kg | intravenous injection, IV; mouse; | DRUGBANK | Toxicity LD50 | 83.0 | mg/kg | 83.0 | mg/kg | intravenous injection, IV; Rattus, Rat; | DRUGBANK |
| Eliminate Route | 30.0 | % | ~30 | % | Urinary excretion; Oral single dose; Unchanged drug; | DRUGBANK | Eliminate Route | 69.0 | % | 69±6 | % | Urinary excretion; Unchanged drug; | RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 15.0 | % | ~15 | % | plasma proteins; | DRUGBANK | Protein Binding | 15.0 | % | 15±3 | % | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 8.0 | mg/kg/day | 8 | mg/kg/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for neonates | 5.0 | mg/kg/day | 5 | mg/kg/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for infants | 10.0 | mg/kg/day | 10 | mg/kg/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for infants | 4.0 | mg/kg/day | 4 | mg/kg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for infants | 6.0 | mg/kg/day | 6 | mg/kg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for children | 10.0 | mg/kg/day | 10 | mg/kg/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for children | 300.0 | mg/day | 300 | mg/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for children | 4.0 | mg/kg/day | 4 | mg/kg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for children | 200.0 | mg/day | 200 | mg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for children | 6.0 | mg/kg/day | 6 | mg/kg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for children | 200.0 | mg/day | 200 | mg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adolescents | 300.0 | mg/day | 300 | mg/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adolescents | 200.0 | mg/day | 200 | mg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adolescents | 6000.0 | mg/day | 6 | g/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adolescents | 9.16666666666667 | mg/day | 220 | mg/hour | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adolescents | 10.0 | mg/kg/day | 10 | mg/kg/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adolescents | 300.0 | mg/day | 300 | mg/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adolescents | 4.0 | mg/kg/day | 4 | mg/kg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adolescents | 200.0 | mg/day | 200 | mg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adolescents | 6.0 | mg/kg/day | 6 | mg/kg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adolescents | 200.0 | mg/day | 200 | mg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adults | 300.0 | mg/day | 300 | mg/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adults | 200.0 | mg/day | 200 | mg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adults | 6000.0 | mg/day | 6 | g/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for adults | 5280.0 | mg/day | 220 | mg/h | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for geriatric | 300.0 | mg/day | 300 | mg/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for geriatric | 200.0 | mg/day | 200 | mg/day | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for geriatric | 6000.0 | mg/day | 6 | g/day | PO, oral | Zantac Injection | ranitidine hydrochloride | PDR |
| Max dose for geriatric | 5280.0 | mg/day | 220 | mg/hour | intravenous injection, IV | Zantac Injection | ranitidine hydrochloride | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1